JP2023546361A5 - - Google Patents
Info
- Publication number
- JP2023546361A5 JP2023546361A5 JP2023521356A JP2023521356A JP2023546361A5 JP 2023546361 A5 JP2023546361 A5 JP 2023546361A5 JP 2023521356 A JP2023521356 A JP 2023521356A JP 2023521356 A JP2023521356 A JP 2023521356A JP 2023546361 A5 JP2023546361 A5 JP 2023546361A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pharmaceutical product
- product according
- aniflorumab
- sle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089355P | 2020-10-08 | 2020-10-08 | |
| US63/089,355 | 2020-10-08 | ||
| US202163178748P | 2021-04-23 | 2021-04-23 | |
| US63/178,748 | 2021-04-23 | ||
| PCT/EP2021/077702 WO2022074123A1 (en) | 2020-10-08 | 2021-10-07 | Treatment of flares in lupus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546361A JP2023546361A (ja) | 2023-11-02 |
| JP2023546361A5 true JP2023546361A5 (https=) | 2024-09-24 |
Family
ID=78269610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521356A Pending JP2023546361A (ja) | 2020-10-08 | 2021-10-07 | ループスにおける紅斑の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240026015A1 (https=) |
| EP (1) | EP4225791A1 (https=) |
| JP (1) | JP2023546361A (https=) |
| KR (1) | KR20230082659A (https=) |
| CN (1) | CN116406296A (https=) |
| AU (1) | AU2021356122B2 (https=) |
| BR (1) | BR112023006328A2 (https=) |
| CA (1) | CA3197055A1 (https=) |
| IL (1) | IL301759A (https=) |
| TW (1) | TW202237647A (https=) |
| WO (1) | WO2022074123A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3216390A1 (en) * | 2021-04-23 | 2022-10-27 | Astrazeneca Ab | Treatment of cutaneous lupus erythematous |
| CN120392997A (zh) * | 2021-04-23 | 2025-08-01 | 阿斯利康(瑞典)有限公司 | 用于皮下注射的抗ifnar1给药方案 |
| IL319505A (en) | 2022-09-14 | 2025-05-01 | Viatris Asia Pacific Pte Ltd | S1P 1 receptor modulators for use in the treatment of diseases mediated by type 1 interferon |
| EP4545090A1 (en) * | 2023-10-27 | 2025-04-30 | Universität Leipzig | Interferon-a receptor immune modulator for use as a medicament |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7662381B2 (en) | 2004-06-21 | 2010-02-16 | Medarex, Inc. | Interferon alpha receptor 1 antibodies and their uses |
| CN101678100A (zh) * | 2006-12-06 | 2010-03-24 | 米迪缪尼有限公司 | 治疗系统性红斑狼疮的方法 |
| KR20160070165A (ko) | 2008-02-08 | 2016-06-17 | 메디뮨 엘엘씨 | Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체 |
| CA2772921A1 (en) | 2009-09-03 | 2011-03-10 | Medimmune, Llc | Type 1 interferon diagnostic |
| RS64263B1 (sr) | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
| CN106243226B (zh) * | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
| EP4494712A3 (en) * | 2019-11-11 | 2025-03-26 | Astrazeneca AB | Type i interferon inhibition in systemic lupus erythematosus |
| EP4157873A2 (en) * | 2020-05-29 | 2023-04-05 | Astrazeneca AB | Treatment of cardiometabolic disease with inhibitors of type i interferon signalling |
-
2021
- 2021-10-06 TW TW110137117A patent/TW202237647A/zh unknown
- 2021-10-07 KR KR1020237015211A patent/KR20230082659A/ko active Pending
- 2021-10-07 BR BR112023006328A patent/BR112023006328A2/pt unknown
- 2021-10-07 WO PCT/EP2021/077702 patent/WO2022074123A1/en not_active Ceased
- 2021-10-07 AU AU2021356122A patent/AU2021356122B2/en active Active
- 2021-10-07 CN CN202180068143.4A patent/CN116406296A/zh active Pending
- 2021-10-07 JP JP2023521356A patent/JP2023546361A/ja active Pending
- 2021-10-07 CA CA3197055A patent/CA3197055A1/en active Pending
- 2021-10-07 US US18/248,280 patent/US20240026015A1/en active Pending
- 2021-10-07 IL IL301759A patent/IL301759A/en unknown
- 2021-10-07 EP EP21794319.0A patent/EP4225791A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023546361A5 (https=) | ||
| US20200030304A1 (en) | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers | |
| US20250205227A1 (en) | Methods for administering corticosteroids | |
| Rasheed et al. | A review of natural steroids and their applications | |
| EP2773325B1 (en) | Liposomal corticosteroids for treatment of inflammatory disorders in humans | |
| ES2260321T3 (es) | Composicion para el tratamiento de transtornos inflamatorios. | |
| JP2014508749A5 (https=) | ||
| JP2021534201A5 (https=) | ||
| EP2322183B1 (en) | Use of prodrugs for ocular intravitreous administration | |
| Caimmi et al. | A new pediatric protocol for rapid desensitization to monoclonal antibodies | |
| JP2024543509A5 (https=) | ||
| JP2024519196A5 (https=) | ||
| JP2022500364A5 (https=) | ||
| CN101938996A (zh) | 用于治疗免疫炎症性紊乱的治疗方案 | |
| JP2024527001A5 (https=) | ||
| JP2024516886A5 (https=) | ||
| Zitt | Symposium Cont. Properties of the Ideal Corticosteroid Therapy. | |
| IL312514A (en) | Corticosteroid reduction in treatment with anti-cd38 antibodies | |
| JP2017141175A (ja) | 多発性硬化症の予防および／または治療剤 | |
| US20210386716A1 (en) | Compositions and methods for blocking the cytokine storm of coronavirus and other medical conditions | |
| IL312515A (en) | Bispecific cd16a binders | |
| JP2011503109A5 (https=) | ||
| JP2022551499A5 (https=) | ||
| Hall | Corticosteroids in autoimmune diseases | |
| Zöllner | Is adrenal suppression in asthmatic children reversible? A case series |